Virus News and Research

Latest Virus News and Research

Study sheds light on poorly understood aspect of interaction of HIV with natural killer cells

Natural killer cells are major weapons in the body's immune system. They keep the body healthy by knocking off tumors and cells infected with viruses, bombarding them with tiny lethal pellets. But natural killer cells are powerless against HIV, a fact that has bedeviled science for over 20 years.

20 Nov 2010

Study refocuses on rare group of neutralizing antibodies against HIV

Although people infected with HIV produce many antibodies against the protein encapsulating the virus, most of these antibodies are strangely ineffective at fighting the disease. A new study suggests why some of the most common of these antibodies don't work: they target the protein in a form it takes after the virus has already invaded the cell, when it's too late, report researchers at Children's Hospital Boston and their colleagues.

20 Nov 2010

Improving immune system to defend against HIV infection

Researchers have been stymied for years over the fact that people infected with the AIDS virus do indeed produce antibodies in response to the pathogen - antibodies that turn out to be ineffective in blocking infection.

19 Nov 2010

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new data at the MIT Center for Biomedical Innovation's Biomanufacturing Summit from its platform efforts aimed at developing RNAi technologies for applications in biologics manufacturing.

19 Nov 2010

Despite progress in testing Americans for HIV, lack of federal/private insurance impedes expansion

With projections that human immunodeficiency virus (HIV) infection rates are increasing in some populations, former Surgeon General Dr. C. Everett Koop -- who charted the nation's policies on HIV/AIDS following the first deaths from AIDS in 1981 -- today issued a stern warning to the public health community: HIV/AIDS continues to be a major epidemic and requires a national mobilization to identify and provide immediate care for many Americans with HIV who remain undiagnosed -- an estimated 200,000 people.

18 Nov 2010

CDC data: Adults remain unvaccinated against preventable infectious illnesses

New data from the Centers for Disease Control and Prevention (CDC) show that adults remain largely unvaccinated against preventable infectious illnesses.

18 Nov 2010

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, commented today on Roche's corporate restructuring and its implications on RNAi therapeutics.

18 Nov 2010

Gen-Probe's APTIMA HPV assay effective for cervical cancer screening: FASE study

In a study published today in the International Journal of Cancer, Gen-Probe's APTIMA HPV Assay provided a better combination of sensitivity and specificity than HPV DNA- or cytology-based tests for cervical cancer screening.

18 Nov 2010

Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases announces today positive top-line 24-week interim data from the Phase 2b ASPIRE (C206) study of TMC435 in treatment-experienced hepatitis C patients.

18 Nov 2010

Scientists solve structure of key protein from Lassa virus

Scientists at Emory University and the University of St. Andrews have solved the structure of a key protein from Lassa virus, which is endemic to West Africa and can cause a deadly hemorrhagic fever.

18 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

miR765 RNA may play a role in development of heart failure: Research

Researchers at the University of Cincinnati (UC) have found a potential genetic target for heart disease, which could lead to therapies to prevent the development of the nation's No. 1 killer in its initial stages.

18 Nov 2010

BioSante announces sale of oncolytic virus technology to Cold Genesys

BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.

18 Nov 2010

Viruses lead to discovery of security system in host cells

Viruses have led scientists at Washington University School of Medicine in St. Louis to the discovery of a security system in host cells.

18 Nov 2010

Nanotrope assay receives U.S. patent for diagnosing influenza and viral infections

Nanotrope, Inc. announced today that it has been issued United States patent #7,829,272 covering its ground-breaking diagnostic test for influenza and other viral infections.

17 Nov 2010

Duke awarded $52.8M federal grant to oversee external quality assurance programs for HIV/AIDS labs

The National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), has awarded Duke University Medical Center up to $52.8 million over the next seven years to support the development, implementation and oversight of external quality assurance programs that monitor laboratories involved in HIV/AIDS research and vaccine trials around the world.

17 Nov 2010

Chimerix’s lipid-conjugated drugs reduces nephrotoxicity: Study

Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.

17 Nov 2010

Swissmedic approves use of plasma components treated with Cerus' INTERCEPT Blood System

Cerus Corporation announced today that the Swiss regulatory body, Swissmedic, has approved the use of plasma components treated with Cerus' INTERCEPT Blood System.

17 Nov 2010

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics Pharmaceuticals, Inc. today announced the initiation of a phase 2 clinical trial of subcutaneous methylnaltrexone in Japan by its collaborator, Ono Pharmaceutical Co., Ltd. The drug, designated ONO-3849 in Japan, is being evaluated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness such as cancer.

17 Nov 2010

New mathematical method predicts dominant strain of influenza virus

Rice University scientists have found a way to predict rapidly whether a new strain of the influenza virus should be included in the annual seasonal flu vaccine. While it sometimes takes new flu strains up to three years to become dominant worldwide, the new method can predict whether they will become dominant as little as two weeks after the sequence first appears in the GenBank database, the National Institutes of Health's collection of all publicly available DNA sequences.

16 Nov 2010

Virus News and Research

Latest Virus News and Research

Study sheds light on poorly understood aspect of interaction of HIV with natural killer cells

Study refocuses on rare group of neutralizing antibodies against HIV

Improving immune system to defend against HIV infection

Alnylam presents data on RNAi technologies at MIT Center Summit

Despite progress in testing Americans for HIV, lack of federal/private insurance impedes expansion

CDC data: Adults remain unvaccinated against preventable infectious illnesses

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

Gen-Probe's APTIMA HPV assay effective for cervical cancer screening: FASE study

Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C

Scientists solve structure of key protein from Lassa virus

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

miR765 RNA may play a role in development of heart failure: Research

BioSante announces sale of oncolytic virus technology to Cold Genesys

Viruses lead to discovery of security system in host cells

Nanotrope assay receives U.S. patent for diagnosing influenza and viral infections

Duke awarded $52.8M federal grant to oversee external quality assurance programs for HIV/AIDS labs

Chimerix’s lipid-conjugated drugs reduces nephrotoxicity: Study

Swissmedic approves use of plasma components treated with Cerus' INTERCEPT Blood System

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

New mathematical method predicts dominant strain of influenza virus

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in